Stock Track | CANSINOBIO Soars 9.68% Intraday on Strong Annual Results, Profit Turnaround and Dividend Plan

Stock Track04-01

CANSINOBIO's stock price surged 9.68% during intraday trading on Wednesday, following the release of its annual financial results.

The company reported full-year revenue of RMB 1.059 billion, a 28.43% year-on-year increase, and a profit attributable to owners of RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, CANSINOBIO announced a shareholder dividend return plan for the next three years with a focus on cash dividends.

The performance growth was primarily fueled by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company's strategies in innovation, commercialization, cost reduction, and operational efficiency enhancements have contributed to the positive results.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116199200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116199200","market":"nz","top_or_hot":-1,"title":"Stock Track | CANSINOBIO Soars 9.68% Intraday on Strong Annual Results, Profit Turnaround and Dividend Plan","media":"Stock Track","content":"<p>CANSINOBIO's stock price surged 9.68% during intraday trading on Wednesday, following the release of its annual financial results.</p><p>The company reported full-year revenue of RMB 1.059 billion, a 28.43% year-on-year increase, and a profit attributable to owners of RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, CANSINOBIO announced a shareholder dividend return plan for the next three years with a focus on cash dividends.</p><p>The performance growth was primarily fueled by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company's strategies in innovation, commercialization, cost reduction, and operational efficiency enhancements have contributed to the positive results.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CANSINOBIO Soars 9.68% Intraday on Strong Annual Results, Profit Turnaround and Dividend Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CANSINOBIO Soars 9.68% Intraday on Strong Annual Results, Profit Turnaround and Dividend Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 12:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO's stock price surged 9.68% during intraday trading on Wednesday, following the release of its annual financial results.</p><p>The company reported full-year revenue of RMB 1.059 billion, a 28.43% year-on-year increase, and a profit attributable to owners of RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, CANSINOBIO announced a shareholder dividend return plan for the next three years with a focus on cash dividends.</p><p>The performance growth was primarily fueled by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company's strategies in innovation, commercialization, cost reduction, and operational efficiency enhancements have contributed to the positive results.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1116199200","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116199200","pubTimestamp":1775019015,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CANSINOBIO's stock price surged 9.68% during intraday trading on Wednesday, following the release of its annual financial results.The company reported full-year revenue of RMB 1.059 billion, a 28.43%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"个股赛道|康希诺生物盘中大涨9.68%年度业绩强劲扭亏为盈及派息计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CANSINOBIO's stock price surged 9.68% during intraday trading on Wednesday, following the release of its annual financial results.The company reported full-year revenue of RMB 1.059 billion, a 28.43% year-on-year increase, and a profit attributable to owners of RMB 27.87 million, marking a turnaround from a loss in the previous year. Additionally, CANSINOBIO announced a shareholder dividend return plan for the next three years with a focus on cash dividends.The performance growth was primarily fueled by sustained revenue increases from its core product, Menhycia, China's first quadrivalent meningococcal conjugate vaccine. The company's strategies in innovation, commercialization, cost reduction, and operational efficiency enhancements have contributed to the positive results.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116199200","isCrawlerRequest":true}